Catergories

You are here

Benefit from nCovid-19

Year 2020 was hit by this global pandemic nCovid -19. Businesses stammered to get back on their legs. However, some sectors not only got back their lost momentum, but also are expected to grow at above average growth rates. Benefit by investing into these companies and industries.

Scheme Logo
  • Equity - Sectoral Fund - Pharma & Health Care
  • ₹ 5,000.00
  • ₹ 189.40
  • 4 Yrs
  • 20.12%
  • ₹ 360,000
  • Calculating...
  • ₹ 299,157.27 Cr
  • 05 Jun 2004
  • Sailesh Raj Bhan , Kinjal Desai
Scheme Logo
  • Equity - Sectoral Fund - Pharma & Health Care
  • ₹ 5,000.00
  • ₹ 13.00
  • 5 Yrs
  • 14.57%
  • ₹ 360,000
  • Calculating...
  • ₹ 146,000.63 Cr
  • 13 Jul 2018
  • Dharmesh Kakkad , Priyanka Khandelwal
Scheme Logo
  • Equity - Sectoral Fund - Pharma & Health Care
  • ₹ 5,000.00
  • ₹ 13.99
  • 4 Yrs
  • 18.71%
  • ₹ 360,000
  • Calculating...
  • ₹ 58,111.74 Cr
  • 02 Jul 2018
  • Vrijesh Kasera
Scheme Logo
  • Equity - Sectoral Fund - Pharma & Health Care
  • ₹ 500.00
  • ₹ 13.59
  • 3 Yrs
  • 21.95%
  • ₹ 360,000
  • Calculating...
  • ₹ 41,235.28 Cr
  • 30 Nov 2018
  • Aditya Khemka , Vinit Sambre , Jay Kothari
Scheme Logo
  • Equity - Sectoral Fund - Pharma & Health Care
  • ₹ 1,000.00
  • ₹ 12.55
  • 3 Yrs
  • 25.50%
  • ₹ 360,000
  • Calculating...
  • ₹ 24,677.85 Cr
  • 10 Jul 2019
  • Dhaval Shah
Scheme Logo
  • Equity - Sectoral Fund - Pharma & Health Care
  • ₹ 5,000.00
  • ₹ 11.26
  • NA
  • 2.69%
  • ₹ 360,000
  • Calculating...
  • ₹ 23,528.15 Cr
  • 28 Dec 2015
  • Meeta Shetty , Rahul Singh
Scheme Logo
  • Equity - Sectoral Fund - Pharma & Health Care
  • ₹ 5,000.00
  • ₹ 13.02
  • 3 Yrs
  • 22.53%
  • ₹ 360,000
  • Calculating...
  • ₹ 3,627.04 Cr
  • 28 Feb 2019
  • Uma Venkatraman
sortSort by Aum

Sort by

close button

Filter By

Reset Filters
close button

Net Asset Value (NAV)

Clear

Consistency - Good

Ratings - High to Low

  • 1
  • 2
  • 3
  • 4
  • 5

Fund Size (AUM)

Clear

Fund House

Clear

Disclaimer: Past results and performance does not mean that the future performance will be the same. Investor is expected to make his own checks and independent evaluations on the suitability of the products and DSPL or its employees shall not bear any direct or indirect responsibility for the same. These are algo generated outputs based on data sourced from third party vendors. Hence, the accuracy of these details is not reconfirmed or guaranteed by DSPL.